Controlled trial of 4-ASA in ulcerative colitis

Area of Science:

• Gastroenterology
• Clinical Pharmacology
• Inflammatory Bowel Disease Research

Background:

• Ulcerative colitis (UC) is a chronic inflammatory bowel disease.
• Mild to moderate UC requires effective and safe treatment options.
• The efficacy of 4-aminosalicylic acid (4-ASA) varies based on disease extent.

Purpose of the Study:

• To evaluate the efficacy and safety of 6 g/day of 4-aminosalicylic acid (4-ASA) in mild to moderate ulcerative colitis.
• To compare 4-ASA efficacy between patients with distal (< 60 cm) and extensive (> 60 cm) disease.
• To assess the safety profile of 4-ASA in this patient population.

Main Methods:

• A six-week, placebo-controlled trial involving 30 subjects with mild to moderate ulcerative colitis.
• Patients were stratified based on disease extent: distal (< 60 cm) or extensive (> 60 cm).
• Efficacy was assessed using scores for diarrhea, bleeding, endoscopic appearance, biopsy results, and physician global assessment. Safety was monitored via symptoms and laboratory values.

Main Results:

• 4-ASA demonstrated significantly greater median percent improvement (42.7%) compared to placebo (21.2%) in the extensive disease group (P < 0.05).
• No significant difference in efficacy was observed between 4-ASA and placebo for the distal disease group or the total study cohort.
• Adverse events included severe dyspepsia in one subject, transient or persistent abnormal AST levels in six subjects, and elevated lipase without pancreatitis in six subjects.

Conclusions:

• Six weeks of 6 g/day 4-ASA is more effective than placebo for mild to moderate ulcerative colitis with extensive disease (> 60 cm).
• 4-ASA did not show superior efficacy compared to placebo for distal ulcerative colitis (< 60 cm).
• The treatment was generally well tolerated, with manageable adverse events observed.